PharmaTher Holdings Ltd · CSE:PHRM
PharmaTher — Investor Presentation (November 2026)
21 slides from PharmaTher's investor presentation, November 2026
Slide 1: 3D Printed Personalized Peptides
3D Printed Personalized Peptides pharmather.com Corporate Presentation · November 2026 CSE: PHRM | OTCQB: PHRRF
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains “forward-looking information” within the meaning of applicable Canadian securities legislation with respect to PharmaTher Holdings Ltd. (the “Company”). All information other than statements of historical fact is forward-looking information, incl
Slide 3: 3D Printed Personalized Peptides
3D Printed Personalized Peptides M3DICINES™ Platform ±1% dose precision CraftMake™ 3D printer · Novel formulations No heat no UV · room temperature PERSONALIZ3D™ Peptides Gummy and Tablet (BPC-157 and KPV) · NAD+ Gummy GMP-ready enclosed · dual printheads CraftMake™ by Craft Health CraftMake™ Distri
Slide 4: Market Opportunity: A large market that mass production cannot serve
Market Opportunity → A large market that mass production cannot serve Personalized medicine is growing. The exact dose, for one patient, is what 3D printing can make $567B → $1.2T $141B → $295B Personalized-medicine market, 2024 → 2033 Peptide therapeutics market, 2025 → 2033 The Problem The Solutio
Slide 5: Why 3D Printing of Medicines
Why 3D Printing of Medicines Five things mass pharmaceutical production can not do economically. MASS PRODUCTION 3D PRINTING Batch size Pays off only at millions of units → Economic from tens to thousands of units Dose A few fixed strengths; patients split pills → Any dose, ±1% accurate, from one re
Slide 6: Our Solution
Our Solution CSE: PHRM | OTCQB: PHRRF
Slide 7: M3DICINES 3D-Printed Medicines Platform
M3DICINES™ 3D-Printed Medicines Platform Precise, room-temperature (no heat, no UV) printing of customized doses on GMP-ready CraftMake™. CRAFTMAKE™ 3D PRINTER DOSAGE FORMS Pellets & mini-tablets Dual-print tablets Gummies & chewables Multi-layered tablets C R A F TC O N T R O L ™ S O F T WA R E Liq
Slide 8: Business Model
Business Model Our moat: exclusive CraftMake™ rights plus our own formulations and data, made possible only by 3D printing. PERSONALIZ3D™ PEPTIDES PARTNERING We sell our printed peptides, direct and through partners. We put the platform to work for others. Peptide gummies In-house placements Heat-fr
Slide 9: PERSONALIZ3D Peptides
PERSONALIZ3D™ Peptides CSE: PHRM | OTCQB: PHRRF
Slide 10: PERSONALIZ3D Peptides and Longevity
PERSONALIZ3D™ Peptides and Longevity Peptides and NAD+/NMN in a gummy, dosed for one patient, with no heat and no UV. GUMMY TA B L E T P E LL E T Peptide Longevity Gummy BPC-157 · KPV · gummy, tablet or pellet NAD+ and NMN in one gummy, two layers Layered, single-dose or core-and-shell gummies, prin
Slide 11: Colon-targeted peptides: first in line for a new U.S. peptide market
Colon-targeted peptides: first in line for a new U.S. peptide market HHS opened a peptide pathway in Oct. 2026; only KPV and BPC-157 are covered for oral use. O U R O P P O R T U N I T Y, O U R M O AT H O W I T WO R K S · A P I L L- I N - P I L L T H AT O P E N S I N T H E C O L O N A new market jus
Slide 12: Telehealth Programs: Unique to our 3D printer technology
Telehealth Programs: Unique to our 3D printer technology Telehealth platforms and pharmacies add a differentiated, documented peptide without building a lab. OUR BRAND PA R T N E R B R A N D S PERSONALIZ3D™ Partner telehealth Telehealth site: an online visit, a Telehealth platforms add our printed p
Slide 13: CraftMake Partnerships
CraftMake™ Partnerships CSE: PHRM | OTCQB: PHRRF
Slide 14: Exclusive North American Rights to CraftMake
Exclusive North American Rights to CraftMake™ 10,000+ potential sites across North America. POT EN T IA L PA RT N ERS & CUSTO ME RS Every placement is infrastructure, not a one-time sale. 503A compound pharmacies ~7,500 U.S. 503A pharmacies alone Each system keeps earning. Telehealth and consumer he
Slide 15: Ways to work with us
Ways to work with us Three ways in, one platform: every partner adds recurring revenue. 50 3 A PH A R M AC I ES C D M O S E R V I C ES B U S I N ES S D EV ELO P M E N T Bring 3D printing in-house Let us make it Build a product together For pharmacies, hospitals, CDMOs and labs. For telehealth, pharm
Slide 16: An asset-light model with three partners, already in place
An asset-light model with three partners, already in place TECHNOLOGY DISPENSING AND R&D M A N U FA C T U R I N G Exclusive North American distributor Center of Excellence GMP contract manufacturer CraftMake™ systems, software, materials and service. PD Labs: a U.S. national 503A compounding FDA-tra
Slide 17: Beyond the core
Beyond the core Our capital goes to peptides and CraftMake™; these advance through partners or non-dilutive funding. NON-DILUTIVE CASH FDA P RO G R A M FU T U R E T E L E HEA LT H >US$25M GAMT deficiency Pediatrics, dysphagia, deprescribing potential ketamine ANDA payments; first expected Q1 2027 3D
Slide 18: Expected Milestones: the next 12 months
Expected Milestones: the next 12 months Peptide launches, CraftMake™ placements and partner agreements. Q4 2026 – 2027 2027 CraftMake™ placements in 503A White-label and CDMO agreements pharmacies 2 4 1 3 From Q4 2026 2027 PERSONALIZ3D™ peptide telehealth Colon-targeted KPV and BPC-157 launch: BPC-1
Slide 19: Leadership across drug development, FDA approvals, compound pharmacy, commercialization, and manufacturing
Leadership across drug development, FDA approvals, compound pharmacy, commercialization, and manufacturing MANAGEMENT & BOARD CS Fabio Chianelli Carmelo Marrelli Dr. Beverly J. Incledon Carlo Sansalone Founder, Chairman & CEO Chief Financial Officer Director Director 25+ years in specialty life scie
Slide 20: Capital structure
Capital structure As at September 30, 2026 91,019,065 1,500,000 ~19% Issued and outstanding common shares Stock options outstanding Insider ownership PHRM (CSE) PHRRF (OTCQB) C O M PA N Y FA C T S Transfer agent Auditor Fiscal year-end Filings Marrelli Trust Company Limited Truster Zweig Raithatha (
Slide 21: Thank You
Thank You info@pharmather.com · 1-888-846-3171 pharmather.com CSE: PHRM | OTCQB: PHRRF
PharmaTher Holdings — Investor Presentation (November 2026) on 6ix